Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Journal of Clinical Oncology

Volumn 24, Issue 27, 2006, Pages 4517-4520

  Jackman, David M ^a,b,c   Holmes, Alison J ^a   Lindeman, Neal ^b,c   Wen, Patrick Y ^a,c,d   Kesari, Santosh ^a,c,d   Borras, Ana M ^a   Bailey, Christopher ^e   De Jong, Francisca ^f   Jänne, Pasi A ^a,b,c   Johnson, Bruce E ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Analytico Medinet   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG SENSITIVITY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; LIVER METASTASIS; LUMBAR PUNCTURE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; MALE; MENINGEAL METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PLEURA EFFUSION; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; BLOOD; DRUG EFFECT; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MENINGIOMA; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 33749046899     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6126     Document Type: Article

References (10)

1. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
2. Mukohara T, Engelman JA, Hanna NH, et al: Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194, 2005
3. Jones HK, Stafford LE, Swaisland HC, et al: A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in phase I clinical trials. J Pharm Biomed Anal 29:221-228, 2002
4. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
5. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922-930, 2003
6. Janne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751-758, 2006
7. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
8. Pao W, Miller V, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
9. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
10. Omuro AM, Kris MG, Miller VA, et al: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344-2348, 2005